Anagrelide is an inhibitor of cyclic AMP phosphodiesterase III and suppress expression of transcription factors including GATA-1 and FOG-1 required for megakaryocytopoiesis, ultimately leading to reduced platelet production.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
Anagrelide is the active ingredient of these drugs:
Brazil Canada Hong Kong New Zealand Singapore
Austria Lithuania Poland
Austria Cyprus Estonia Finland France
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):